EE9800219A - Uued 19-nor-pregneeni derivaadid - Google Patents

Uued 19-nor-pregneeni derivaadid

Info

Publication number
EE9800219A
EE9800219A EE9800219A EE9800219A EE9800219A EE 9800219 A EE9800219 A EE 9800219A EE 9800219 A EE9800219 A EE 9800219A EE 9800219 A EE9800219 A EE 9800219A EE 9800219 A EE9800219 A EE 9800219A
Authority
EE
Estonia
Prior art keywords
new
pregnene derivatives
pregnene
derivatives
Prior art date
Application number
EE9800219A
Other languages
English (en)
Estonian (et)
Other versions
EE03692B1 (et
Inventor
Piasco Alain
Lafay Jean
Delansorne R�mi
Paris Jacques
Pascal Jean-Claude
Original Assignee
Laboratoire Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Theramex filed Critical Laboratoire Theramex
Publication of EE9800219A publication Critical patent/EE9800219A/xx
Publication of EE03692B1 publication Critical patent/EE03692B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
EE9800219A 1996-01-22 1997-01-17 19-nor-pregneeni derivaadid, mis omavad progestaatilist toimet ja neid sisaldavad farmatseutilised kompositsioonid EE03692B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96400146A EP0785212A1 (en) 1996-01-22 1996-01-22 New 19-nor-pregnene derivatives
PCT/EP1997/000357 WO1997027210A1 (en) 1996-01-22 1997-01-17 New 19-nor-pregnene derivatives

Publications (2)

Publication Number Publication Date
EE9800219A true EE9800219A (xx) 1998-12-15
EE03692B1 EE03692B1 (et) 2002-04-15

Family

ID=8225217

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800219A EE03692B1 (et) 1996-01-22 1997-01-17 19-nor-pregneeni derivaadid, mis omavad progestaatilist toimet ja neid sisaldavad farmatseutilised kompositsioonid

Country Status (36)

Country Link
US (1) US6180803B1 (xx)
EP (2) EP0785212A1 (xx)
JP (2) JP4368945B2 (xx)
KR (1) KR100396902B1 (xx)
CN (1) CN1187366C (xx)
AP (1) AP1176A (xx)
AR (1) AR005500A1 (xx)
AT (1) ATE184015T1 (xx)
BR (1) BR9707064A (xx)
CA (1) CA2243504C (xx)
CO (1) CO4810230A1 (xx)
CZ (1) CZ292047B6 (xx)
DE (1) DE69700470T2 (xx)
DZ (1) DZ2169A1 (xx)
EE (1) EE03692B1 (xx)
ES (1) ES2140961T3 (xx)
GR (1) GR3031954T3 (xx)
HK (1) HK1018216A1 (xx)
HU (1) HU221796B1 (xx)
ID (1) ID15840A (xx)
IL (1) IL125379A (xx)
IS (1) IS1902B (xx)
JO (1) JO1971B1 (xx)
MY (1) MY116845A (xx)
NO (1) NO309572B1 (xx)
NZ (1) NZ330954A (xx)
OA (1) OA10813A (xx)
PE (1) PE55998A1 (xx)
PL (1) PL185608B1 (xx)
RU (1) RU2166509C2 (xx)
SI (1) SI0886645T1 (xx)
TN (1) TNSN97015A1 (xx)
TR (1) TR199801399T2 (xx)
TW (1) TW411345B (xx)
WO (1) WO1997027210A1 (xx)
ZA (1) ZA97521B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
EP1307232B1 (en) 2000-08-03 2007-03-07 Antares Pharma IPL AG Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
DK1660009T3 (en) * 2003-09-03 2015-04-27 Miscon Trading S A METHODS OF TREATING ENDOMETRIOSIS
MXPA06003316A (es) * 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9173915B1 (en) * 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN109364020B (zh) * 2015-09-02 2021-12-28 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593524A1 (de) * 1951-01-28 1970-08-13 Schering Ag Verfahren zur Herstellung von 1,2alpha-Methylen-19-nor-steroiden
DE1087127B (de) * 1958-12-13 1960-08-18 Schering Ag Verfahren zur Herstellung neuer progestativ wirksamer Ester von 2-Methyl-Steroiden
FR1405214A (fr) * 1962-06-21 1965-07-09 Rhone Poulenc Sa Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation
FR1525916A (fr) * 1965-11-09 1968-05-24 Schering Ag Stéroïdes portant un groupe méthylène en position 1.2 et leur préparation
US3891677A (en) * 1967-06-06 1975-06-24 Schering Corp 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones
US3835160A (en) * 1967-06-06 1974-09-10 Schering Corp 3{40 -keto-2{40 ,3{40 -seco-1{40 -(2{40 )-yne steroidal derivatives, methods for their manufacture, and compounds produced thereby
BE757286A (fr) * 1969-10-10 1971-04-09 Ciba Geigy Nouvelle 6alpha-methyl-19-nor progesterone et procede pour sa preparation
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
DE3402330A1 (de) * 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate

Also Published As

Publication number Publication date
TW411345B (en) 2000-11-11
HUP9900684A2 (hu) 1999-07-28
ES2140961T3 (es) 2000-03-01
OA10813A (en) 2003-01-28
EP0886645B1 (en) 1999-09-01
NZ330954A (en) 1998-10-28
WO1997027210A1 (en) 1997-07-31
JO1971B1 (en) 1997-12-15
IS1902B (is) 2003-11-20
ID15840A (id) 1997-08-14
BR9707064A (pt) 1999-12-28
DE69700470D1 (de) 1999-10-07
CA2243504A1 (en) 1997-07-31
EE03692B1 (et) 2002-04-15
KR100396902B1 (ko) 2004-05-03
PL327998A1 (en) 1999-01-04
KR19990081895A (ko) 1999-11-15
EP0785212A1 (en) 1997-07-23
CA2243504C (en) 2004-03-30
NO983356L (no) 1998-07-21
CN1187366C (zh) 2005-02-02
TNSN97015A1 (fr) 2005-03-15
US6180803B1 (en) 2001-01-30
EP0886645A1 (en) 1998-12-30
IL125379A0 (en) 1999-03-12
JP2000503980A (ja) 2000-04-04
HU221796B1 (hu) 2003-01-28
IL125379A (en) 2003-05-29
MY116845A (en) 2004-04-30
RU2166509C2 (ru) 2001-05-10
CZ230798A3 (cs) 1998-11-11
HUP9900684A3 (en) 1999-11-29
AR005500A1 (es) 1999-06-23
AU708135B2 (en) 1999-07-29
TR199801399T2 (xx) 1998-10-21
ZA97521B (en) 1997-08-04
DE69700470T2 (de) 2000-03-30
PL185608B1 (pl) 2003-06-30
CO4810230A1 (es) 1999-06-30
SI0886645T1 (en) 1999-12-31
AP9801299A0 (en) 1998-09-30
JP4368945B2 (ja) 2009-11-18
DZ2169A1 (fr) 2002-12-25
CZ292047B6 (cs) 2003-07-16
JP2009167188A (ja) 2009-07-30
ATE184015T1 (de) 1999-09-15
NO309572B1 (no) 2001-02-19
AP1176A (en) 2003-06-30
HK1018216A1 (en) 1999-12-17
NO983356D0 (no) 1998-07-21
PE55998A1 (es) 1998-10-01
GR3031954T3 (en) 2000-03-31
CN1209811A (zh) 1999-03-03
AU1595597A (en) 1997-08-20
IS4800A (is) 1998-07-21

Similar Documents

Publication Publication Date Title
ATE323682T1 (de) Aryl-pyrimidin-derivate
ATE261942T1 (de) 6-phenylpyridinderivate
IS1902B (is) Nýjar 19-nor-pregnene afleiður
PT934320E (pt) Derivados de naftiridina
ATE260243T1 (de) N-aroylphenylalaninderivate
ATE235220T1 (de) Resorcinderivate
NO981946D0 (no) Imidazoquinazolin-derivater
NO952854D0 (no) 1-arylpyrimidin-derivater
DE59508427D1 (de) 3-aryl-4-hydroxy-delta 3 -dihydrothiophenon-derivate
DE69817186D1 (de) Diaminorhodamin-derivate
DE69732576D1 (de) Tetrahydrobenzindolon-derivate
BR9709065A (pt) Derivados de alquilaminobenzotiazole e-benzoxazol
DE69430587D1 (de) Pyrimidin-acyclonukleosid-derivate
ATE440854T1 (de) 5-deoxy-cytidin-derivate
FI960367A (fi) Uusia dialkoksipyridinyylibentsimidatsolijohdannaisia
EE9900182A (et) 2-metoksüfenüülpiperasiini derivaadid
PT931087E (pt) Novos derivados de piranosido
BR9507892A (pt) Novos derivados de diamino-metilideno
ATE292632T1 (de) Cis-disubstituierte aminocycloalkyl-pyrrolidin- derivate
PT906279E (pt) Derivados de pirrol
DE69828780D1 (de) Amidinocamptpthecin-derivate
DE59509209D1 (de) Diphenyloxazolin-derivate
BR9711681A (pt) Novos m-todos
BR9509877A (pt) Novos derivados de pirimidinilóxi-e piridimidinilamino- etilfenil-dioxolano
DE69510792T2 (de) Naphtochinonderivate

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20120117